Lipocine (LPCN) to Release Earnings on Thursday

Lipocine (NASDAQ:LPCN) is anticipated to release its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Lipocine to post earnings of ($0.60) per share and revenue of $0.1160 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 9:30 AM ET.

Lipocine Price Performance

Shares of Lipocine stock opened at $8.43 on Thursday. The firm has a market cap of $46.79 million, a price-to-earnings ratio of -8.26 and a beta of 0.98. The stock’s 50-day moving average is $8.89 and its 200-day moving average is $5.11. Lipocine has a one year low of $2.52 and a one year high of $12.37.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. HC Wainwright restated a “buy” rating and issued a $15.00 target price (up from $7.00) on shares of Lipocine in a research note on Wednesday, January 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lipocine in a report on Monday, December 29th. Finally, Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a research report on Sunday, February 15th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Institutional Investors Weigh In On Lipocine

Several large investors have recently made changes to their positions in LPCN. Squadron Capital Management LLC bought a new position in shares of Lipocine in the fourth quarter valued at $4,256,000. Diadema Partners LP bought a new stake in Lipocine during the fourth quarter worth $2,095,000. Ikarian Capital LLC acquired a new stake in Lipocine in the fourth quarter valued at $1,602,000. Geode Capital Management LLC grew its position in shares of Lipocine by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after acquiring an additional 1,374 shares during the period. Finally, Boothbay Fund Management LLC bought a new position in shares of Lipocine in the 4th quarter valued at about $441,000. Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.